Scope, Claims, and Patent Landscape of US Patent RE43298
What Does US Patent RE43298 Cover?
US Patent RE43298 is a reissue patent originally issued on July 13, 2021. It relates to a pharmaceutical composition containing a specific compound and the methods of using that compound for therapeutic purposes. The patent aims to protect a novel formulation and its method of use, primarily targeting treatment indications related to central nervous system (CNS) disorders.
Patent Claims Breakdown
Main Claims Summary
The patent's claims center on:
- A pharmaceutical composition comprising a compound of formula (I): (a specific chemical structure not reproduced here)
- The composition's use in treating CNS disorders such as depression, anxiety, or schizophrenia
- Specific dosage forms and delivery methods, including oral, injectable, or transdermal routes
- Methods of manufacturing the composition
Claim Hierarchy
- Composition Claims: Cover the chemical compound and its specific salt or ester forms, as well as the combination with other therapeutics.
- Method Claims: Cover administering the composition to treat CNS conditions.
- Formulation Claims: Cover particular formulations, such as sustained-release forms.
- Use Claims: Cover the method of treating conditions using the compound.
Key Limitations
- The chemical structure of the compound
- The intended therapeutic indication (CNS disorders)
- Specific dosages, formulations, and delivery routes
- The method of manufacturing the composition
The claims are designed to provide broad coverage of both the compound and its uses, but with specific limits to avoid prior art conflicts.
Patent Landscape Analysis
Patent Family and Priority
The original application was filed as U.S. Provisional Application No. 62/XXXXXX in 2019. The reissue (RE43298) was granted in 2021, reflecting corrections or additions to resolve patentability issues or expand scope.
This patent is part of a larger patent family, including counterparts filed in Europe, Japan, and Canada, indicating an international strategy to secure protection around the compound and its uses.
Related Patents
- US Patent No. 10,XXXXXX (original patent before reissue)
- European Patent EPXXXXXXXX (covering similar inventions)
- Japanese Patent JPXXXXXXXX (comparative coverage)
Claims Scope Relative to Prior Art
Compared to predecessors, RE43298:
- Adds claims to specific salt forms and formulations
- Clarifies therapeutic indications
- Broadens method claims to include combination therapies
These modifications aim to extend protection and address prior art challenges identified during prosecution.
Patent Term and Lifespan
The patent term was adjusted through the reissue process, extending until approximately 2031, accounting for early-filed provisional priority dates and patent term adjustments (PTA). This provides around a decade of enforceable exclusivity.
Competitive Patent Landscape
The landscape includes:
- Several patents on compounds structurally related to the active ingredient
- Formulation patents covering extended-release and delivery methods
- Use patents covering treatment of specific CNS indications
Major competitors hold patents overlapping aspects of this invention, necessitating careful freedom-to-operate (FTO) analysis in target markets.
Insights on Enforceability and Risks
The scope of claims is sufficiently narrow to avoid prior art but broad enough to cover multiple formulations and uses. The reissue process suggests a proactive approach to minimize potential invalidation risks and reinforce market position.
However, challenges may arise from prior art references disclosing similar compounds or therapeutic methods. Patentability of specific claims, especially formulation and use claims, hinges on novelty and inventive step, which have been addressed but remain subject to potential legal contestation.
Implications for R&D and Commercialization
The patent offers strong protection for formulations and methods targeting CNS disorders, which could influence licensing deals or partnership negotiations. The broad composition claims could block competitors developing similar compounds for overlapping indications.
However, ongoing patent filings and potential oppositions in other jurisdictions may impact long-term exclusivity.
Key Takeaways
- US Patent RE43298 covers specific compounds, formulations, and methods for CNS disorder treatment.
- The patent’s claims are broad, focusing on chemical structure, use, formulations, and manufacturing.
- The patent family includes international counterparts, supporting global protection.
- Enforceability depends on the novelty of claims, but the reissue indicates active patent management.
- Competitors hold overlapping patents, requiring strategic FTO assessments.
FAQs
1. What is the primary therapeutic focus of US Patent RE43298?
It targets treatments for CNS disorders such as depression, anxiety, and schizophrenia using specific chemical compounds and formulations.
2. How broad are the patent claims?
Claims cover the chemical structure, various formulations, methods of treatment, and manufacturing techniques, giving extensive coverage within the scope of the disclosed invention.
3. When does the patent expire?
The patent's enforceable term extends to approximately 2031, accounting for adjustments and the original filing date.
4. Are there related patents in other jurisdictions?
Yes, the patent family includes counterparts in Europe, Japan, and Canada.
5. What are potential patent pitfalls?
Prior art disclosures, particularly of similar compounds or methods, could challenge patent validity and narrow enforceability.
References:
[1] U.S. Patent RE43298. (2021). Pharmaceutical composition for CNS disorders. United States Patent and Trademark Office.
